FOXO3 is involved in the tumor necrosis factor-driven inflammatory response in fibroblast-like synoviocytes.


Journal

Laboratory investigation; a journal of technical methods and pathology
ISSN: 1530-0307
Titre abrégé: Lab Invest
Pays: United States
ID NLM: 0376617

Informations de publication

Date de publication:
05 2019
Historique:
received: 06 06 2018
accepted: 26 11 2018
revised: 14 11 2018
pubmed: 27 1 2019
medline: 1 7 2020
entrez: 26 1 2019
Statut: ppublish

Résumé

Fibroblast-like synoviocytes (FLS) are major contributors to joint inflammation in rheumatoid arthritis (RA). Forkhead box O 3 (FOXO3) perturbations in immune cells are increasingly linked to RA pathogenesis. Here, we show that FOXO3 is distinctly inactivated/phosphorylated in the FLS of rheumatoid synovitis. In vitro, stimulation of FLS with tumor necrosis factor-alpha α (TNFα) induced a rapid and sustained inactivation of FOXO3. mRNA profiling revealed that the inactivation of FOXO3 is important for the sustained pro-inflammatory interferon response to TNFα (CXCL9, CXCL10, CXCL11, and TNFSF18). Mechanistically, our studies demonstrate that the inactivation of FOXO3 results from TNF-induced downregulation of phosphoinositide-3-kinase-interacting protein 1 (PIK3IP1). Thus, we identified FOXO3 and its modulator PIK3IP1 as a critical regulatory circuit for the inflammatory response of the resident mesenchymal cells to TNFα and contribute insight into how the synovial tissue brings about chronic inflammation that is driven by TNFα.

Identifiants

pubmed: 30679758
doi: 10.1038/s41374-018-0184-7
pii: S0023-6837(22)02620-4
doi:

Substances chimiques

Forkhead Box Protein O3 0
Intracellular Signaling Peptides and Proteins 0
Membrane Proteins 0
PIK3IP1 protein, human 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

648-658

Auteurs

Bernhard Brandstetter (B)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090, Vienna, Austria.

Karolina Dalwigk (K)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090, Vienna, Austria.

Alexander Platzer (A)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090, Vienna, Austria.

Birgit Niederreiter (B)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090, Vienna, Austria.

Felix Kartnig (F)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090, Vienna, Austria.

Anita Fischer (A)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090, Vienna, Austria.

Gregory I Vladimer (GI)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090, Vienna, Austria.

Ruth A Byrne (RA)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090, Vienna, Austria.

Florian Sevelda (F)

Department of Orthopaedics, Medical University of Vienna, 1090, Vienna, Austria.

Johannes Holinka (J)

Department of Orthopaedics, Medical University of Vienna, 1090, Vienna, Austria.

Thomas Pap (T)

Institute of Musculoskeletal Medicine, University Hospital Muenster, 48149, Muenster, Germany.

Günter Steiner (G)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090, Vienna, Austria.

Giulio Superti-Furga (G)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090, Vienna, Austria.
Center for Physiology and Pharmacology, Medical University of Vienna, 1090, Vienna, Austria.

Josef S Smolen (JS)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090, Vienna, Austria.

Hans P Kiener (HP)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090, Vienna, Austria.

Thomas Karonitsch (T)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090, Vienna, Austria. thomas.karonitsch@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH